Hospital length of stay for severe COVID-19 patients: implications for Remdesivir’s value

Michaela R Anderson; Peter B. Bach; Matthew R. Baldwin

doi:10.1101/2020.08.10.20171637

Abstract
Full Text
Info/History
Metrics
Data/Code
Preview PDF

Data Availability

Data sharing would be considered under appropriate IRB oversight and approval.

Comments

medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions and read our Comment Policy before commenting. The content of a comment is not endorsed by medRxiv.

Community Reviews

medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors.

Automated Evaluations

Certain services provide automated analysis of preprints. Analyses invited by the authors are displayed at the top of this tab. Those done independently of authors are shown underneath . None of these analyses is endorsed by medRxiv.

Hospital length of stay for severe COVID-19 patients: implications for Remdesivir’s value

Data Availability

Subject Area

Citation Manager Formats

Hospital length of stay for severe COVID-19 patients: implications for Remdesivir’s value

Data Availability

Subject Area

Follow this preprint